Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
Curie-Cancer and GamaMabs Pharma renew their research partnership to develop an antibody for gynecological cancers
Category Archives: News & Events
GamaMabs Pharma signs a Collaboration Agreement with Mayo Clinic
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, Nathalie Kersual et al., mAbs October 2014
mAbs journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Nathalie Kersual, Véronique Garambois, Thierry Chardès, Jean-Pierre Pouget, Imed Salhi, Caroline Bascoul-Mollevi, Frédéric Bibeau, Muriel Busson, Henri Vié, Béatrice Clémenceau, Christian K Behrens, Pauline Estupina, André Pèlegrin & Isabelle Navarro-Teulon (2014) The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, mAbs, 6:5, 1314-1326
GamaMabs Pharma announces two scientific communications on its AMHR2 project
Two studies on AMHR2 project were accepted for a publication in mAbs journal and a poster by Institut Curie (Paris, France) at the 10th Biennial Ovarian Cancer Research Symposium (Seattle, 8-9 September 2014)
Start-up Magazine – April 2014
Start-up magazine publishes an article on GamaMabs Pharma in its April 2014 issue dedicated to antibodies.
GamaMabs Pharma announces two financings totaling €1.1 million
Alto Invest joins GamaMabs investors with a €0.5m equity financing and Bpifrance awards a €0.6m reimbursable aid for the development of 3C23K program in ovarian cancer.
Funding of a new French biotechnologies company specialized in cancer
LFB S.A and Bpifrance announce the creation of GamaMabs Pharma, a new biotechnologies company specialized in the development of a new therapeutic antibody for the treatment of ovarian cancer. The first equity funding led by Bpifrance through the InnoBio fund, next to IRDINOV and IXO Private Equity totalizes €3.1M.